Results 141 to 150 of about 100,255 (311)

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

open access: yesBJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund   +4 more
wiley   +1 more source

Correction: On Bayesian modeling of censored data in JAGS

open access: yesBMC Bioinformatics, 2022
Xinyue Qi, Shouhao Zhou, Martyn Plummer
openaire   +2 more sources

The Dynamics of Neurofilament Light Chain in Spinal Muscular Atrophy

open access: yesAnnals of Neurology, EarlyView.
Objective Newborn screening (NBS) for spinal muscular atrophy (SMA) facilitates early diagnosis and treatment for affected individuals. However, fluid biomarkers that provide early insights into disease activity and outcomes in a neonatal cohort and those unable to access (due to reimbursement criteria) or deferring immediate treatment are lacking ...
Arlene D'Silva   +13 more
wiley   +1 more source

Quantiles for Fractions and Other Mixed Data [PDF]

open access: yes
This paper studies the estimation of quantile regression for fractional data, focusing on the case where there are mass-points at zero or/and one. More generally, we propose a simple strategy for the estimation of the conditional quantiles of data from ...
J. M. C. Santos Silva   +1 more
core  

Daily‐Life, Sensor‐Derived Tremor Measures Are Sensitive to Progression in Early Parkinson's Disease

open access: yesAnnals of Neurology, EarlyView.
Objective Sensitive outcome measures are critical for evaluating the efficacy of novel treatments for Parkinson's disease (PD). In this study, we assess the sensitivity to change of sensor‐derived daily‐life tremor measures over 2 years in unmedicated and medicated persons with early PD.
Nienke A. Timmermans   +10 more
wiley   +1 more source

Inference under progressively type II right censored sampling for certain lifetime distributions

open access: yes, 2009
In this paper, estimation of the parameters of a certain family of two-parameter lifetime distributions based on progressively Type II right censored samples (including ordinary Type II right censoring) is studied.
Yu, K, Wang, BX, Jones, MC
core  

Cerebrospinal Fluid Amyloid‐β Biomarkers Predict Future Hemorrhage in Patients with Cerebral Amyloid Angiopathy

open access: yesAnnals of Neurology, EarlyView.
Objective Accurately predicting future hemorrhagic events in patients with cerebral amyloid angiopathy (CAA) remains a major clinical challenge. It is unknown whether cerebrospinal fluid (CSF) biomarkers of amyloid‐beta (Aβ) pathology are associated with increased hemorrhage risk in this population.
Philipp Arndt   +15 more
wiley   +1 more source

A Partially Linear Censored Quantile Regression Model for Unemployment Duration [PDF]

open access: yes
Censored Regression Quantile (CRQ) methods provide a powerful and flexible approach for the analysis of censored survival data when standard linear models are felt to be appropriate.
Portnoy, Stephen, Neocleous, Tereza
core  

Genetic‐Proteomic Integration Identifies Predictive Plasma Proteins for Multiple Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) develops after a prolonged preclinical phase. Identifying circulating biomarkers that capture this early biology can improve risk stratification and guide intervention. We aimed to identify plasma proteins driving MS susceptibility using large‐scale proteogenomic integration and to evaluate their prediagnostic ...
Yuan Ding   +5 more
wiley   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

open access: yesAnnals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy